Symbols

PRLD

Prelude·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About PRLD

Prelude Therapeutics Incorporated

A clinical-stage precision oncology company that developing innovative drug candidates for cancer

Industry

Biological Technology

Established Date

02/05/2016

Listing Date

09/25/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.preludetx.com

Security Type

Common stock

Office address

175 Innovation Boulevard, Wilmington, Delaware 19805

Business

Introduction

Prelude Therapeutics Incorporated, founded in Delaware on February 5, 2016, is a clinical-stage precision oncology company dedicated to discovering and developing small molecule therapies optimized for key driving mechanisms of highly unmet cancer needs.

Company Financials

EPS

PRLD has released its 2025 Q4 earnings. EPS was reported at -0.2, versus the expected -0.13, missing expectations. The chart below visualizes how PRLD has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

PRLD has released its 2025 Q4 earnings report, with revenue of 5.64M, reflecting a YoY change of 41.00%, and net profit of -16.46M, showing a YoY change of 42.72%. The Sankey diagram below clearly presents PRLD's revenue sources and cost distribution.